{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T09:47:28Z","timestamp":1794995248196,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K10653"],"award-info":[{"award-number":["JP24K10653"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019702","name":"Tokyo Metropolitan Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030953","name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25dk0207068"],"award-info":[{"award-number":["JP25dk0207068"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24he2202020"],"award-info":[{"award-number":["JP24he2202020"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tjpad.2026.100562","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:23:44Z","timestamp":1775316224000},"page":"100562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Amyloid-related imaging abnormalities in Japanese patients with Alzheimer\u2019s disease treated with Lecanemab: A real-world study"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9314-7997","authenticated-orcid":false,"given":"Ryosuke","family":"Shimasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-1932","authenticated-orcid":false,"given":"Taro","family":"Bannai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-4714","authenticated-orcid":false,"given":"Keiko","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-732X","authenticated-orcid":false,"given":"Fumio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya Midori","family":"Tokumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-5314","authenticated-orcid":false,"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tjpad.2026.100562_bib0001","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer's disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with Lecanemab, an anti-a\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0003","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100562_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of a phase III trial of Lecanemab in early Alzheimer's disease","volume":"12","author":"Chen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 Lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100562_bib0007","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ggi.14945","article-title":"How will the emergence of Lecanemab change dementia treatment?","volume":"24","author":"Iwata","year":"2024","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.tjpad.2026.100562_bib0008","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) J. Optimal use guidelines for Lecanemab (in Japanese). Published December 20, 2023. Accessed July 9, 2025."},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0009","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100562_bib0010","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100562_bib0011","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100562_bib0012","first-page":"1","article-title":"Practical brain MRI guidelines for anti-a\u03b2 antibody treatment in early symptomatic Alzheimer\u2019s disease","author":"Kakeda","year":"2025","journal-title":"Jpn J Radiol"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100562_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100562_bib0014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100562_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer's disease: appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100562_bib0016","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12194-022-00653-7","article-title":"Decreased imaging time of amyloid PET using [(18)F]florbetapir can maintain quantitative accuracy","volume":"15","author":"Wagatsuma","year":"2022","journal-title":"Radiol Phys Technol"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100562_bib0017","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s12149-022-01769-x","article-title":"Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease","volume":"36","author":"Imabayashi","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.tjpad.2026.100562_bib0018","article-title":"Biomarker heterogeneity in patients receiving Lecanemab in the real world","author":"Kurihara","year":"2025","journal-title":"medRxiv"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100562_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3092","article-title":"Development of software for measuring brain amyloid accumulation using (18) F-florbetapir PET and calculating global Centiloid scale and regional Z-score values","volume":"13","author":"Matsuda","year":"2023","journal-title":"Brain Behav"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100562_bib0020","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-240185","article-title":"Relationship between cerebrospinal fluid Alzheimer's Disease biomarker values measured via lumipulse assays and conventional ELISA: single-center experience and systematic review","volume":"99","author":"Kurihara","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100562_bib0021","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/acn3.51681","article-title":"Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(\u00ae) system","volume":"9","author":"Nojima","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.tjpad.2026.100562_bib0022","series-title":"Common terminology criteria for adverse events (CTCAE)","first-page":"5","author":"UDoHaH","year":"2017"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100562_bib0023","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with Donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13195-025-01886-5","article-title":"Real-world application of Lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis","volume":"17","author":"Shang","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100562_bib0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese patients with early Alzheimer's Disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol Ther"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100562_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100220","article-title":"Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE","volume":"12","author":"Sima","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100562_bib0027","article-title":"AI-assisted detection of amyloid-related imaging abnormalities (ARIA): promise and pitfalls","author":"Petrella","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100562_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.55800","article-title":"Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities","volume":"7","author":"Sima","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0029","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte-endothelial interactions at the blood-brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","article-title":"Astrocytes: biology and pathology","volume":"119","author":"Sofroniew","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100562_bib0031","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100562_bib0032","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/jnc.15565","article-title":"Reactive astrogliosis: a friend or foe in the pathogenesis of Alzheimer's disease","volume":"164","author":"Kumar","year":"2023","journal-title":"J Neurochem"},{"key":"10.1016\/j.tjpad.2026.100562_bib0033","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fncel.2018.00193","article-title":"Emerging roles of astrocytes in neuro-vascular unit and the tripartite synapse with emphasis on reactive gliosis in the context of Alzheimer's disease","volume":"12","author":"Liu","year":"2018","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2040-7378-5-4","article-title":"Blood brain barrier breakdown as the starting point of cerebral small vessel disease? - new insights from a rat model","volume":"5","author":"Schreiber","year":"2013","journal-title":"Exp Transl Stroke Med"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100562_bib0035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0271678X15606141","article-title":"Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment","volume":"36","author":"Shams","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100562_bib0036","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000003556","article-title":"Blood-brain barrier leakage is more widespread in patients with cerebral small vessel disease","volume":"88","author":"Zhang","year":"2017","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100562_bib0037","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1002\/alz.13874","article-title":"Heterogeneous blood-brain barrier dysfunction in cerebral small vessel diseases","volume":"20","author":"Ying","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100562_bib0038","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-200755","article-title":"Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage","volume":"78","author":"Asken","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100562_bib0039","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1093\/brain\/awae211","article-title":"Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline","volume":"147","author":"Peretti","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2026.100562_bib0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2021.02.012","article-title":"Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease","volume":"103","author":"Bettcher","year":"2021","journal-title":"Neurobiol Aging"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100562_bib0041","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.3174\/ajnr.A8822","article-title":"Are deep white matter hyperintensities associated with amyloid-related imaging abnormalities in patients with Alzheimer Disease treated with Lecanemab?","volume":"46","author":"Rohatgi","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100562_bib0042","doi-asserted-by":"crossref","first-page":"869","DOI":"10.14283\/jpad.2024.139","article-title":"Greater white matter hyperintensity volume is associated with the number of microhemorrhages in preclinical Alzheimer's disease","volume":"11","author":"Shirzadi","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100562_bib0043","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/STROKEAHA.118.023355","article-title":"Perioperative cerebral microbleeds after adult cardiac surgery","volume":"50","author":"Patel","year":"2019","journal-title":"Stroke"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:40:43Z","timestamp":1780339243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2274580726000865"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100562","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyloid-related imaging abnormalities in Japanese patients with Alzheimer\u2019s disease treated with Lecanemab: A real-world study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100562"}}